• The full-service CRO

    The CRO of choice
    by the leading Investigators

    and Sites

    Serving clients ranging
    from Big Pharma

    to Start-ups

    Combining Global Coverage with true Local Expertise

    In the United States, Europe, Russia and Asia, since 2001

    Continue to the website
    Download brochure

Flu Vaccine Trial in Pregnant Women Awarded

GCT has been awarded a multicenter flu vaccine clinical trial in Russia. It will be carried out with participation of approximately 500 pregnant women at screening, and with a follow-up extension to babies.

GCT possesses previous experience in conducting multinational studies in pregnant women with participation of 1000+ subject.

November 10, 2021

GCT to Manage Bioequivalence Study in Healthy Volunteers

Last week, GCT has been selected to conduct a bioequivalence clinical trial in a calcium channel blocker, Manidipine.

GCT will manage the full-service study support including medical writing, clinical and medical monitoring, regulatory, project management, site and vendor management, data management and biostatistics.

November 9, 2021

GCT passed Sponsor Audit with no findings

GCT has recently passed a sponsor audit in St. Petersburg, Russia.

The sponsor company is one of the leading vaccine developers with a rapid clinical pipeline. The remote audit was conducted in order to confirm GCT’s adherence to GCP, the Declaration of Helsinki, the Rules of proper clinical practice of the Eurasian Economic Union, the local Russian regulations, and the sponsor’s policies. No major findings were identified. Following the audit, GCT was approved as a vendor of category “A” and authorized to participate in the sponsor’s commercial tenders.

September 28, 2021

GCT to Manage Phase III COVID-19 Study

Global Clinical Trials is adding yet another COVID-19 clinical trial to its Infectious Disease portfolio. As a part of a multi-national project, GCT will manage the double-blind Phase III study in adult patients with COVID-19 in Russia.

After a thorough feasibility analysis, GCT clinical team together with the Sponsor selected the clinical sites with the most enrollment potential.

August 30, 2021

End of Enrollment for the Sore Throat Trial

The enrollment was completed for a phase IV, multicenter, randomized, non-inferiority trial by reaching the study-wide goal of including 360 patients.

GCT is responsible for managing project in Russia where the patient enrolment began in August 2020.

July 29, 2021

First Patient in Idiopathic Pulmonary Fibrosis Study

The first patient has been included in this clinical trial in Russia. The study is a Phase 2, Multi-Centre, Open-Label, Single-Arm Trial Investigating the Safety, Efficacy of IP aiming to help those suffering from IPF.

Idiopathic pulmonary fibrosis is a chronic, progressive lung disease. When it occurs, scar tissue (fibrosis) is accumulated in the lungs, making it very difficult for the lungs to transport oxygen efficiently into the bloodstream.

July 13, 2021

Meet our clients

All trademarks, brand names and logotypes are intellectual property of their respective owners.

Upcoming meetings

CPhI India Online

Online event
2021, November 15—30

Subscribe to our mailing list

Marketing Permissions

Please select all the ways you would like to hear from Global Clinical Trials (GCT):

You can unsubscribe at any time by clicking the link in the footer of our emails. Please see our Privacy Policy. We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.


GCT is a CRO experienced in performing clinical research in the USA, Europe, Russia and India.

We are a full-service clinical development provider, offering feasibility analysis, regulatory submission, site selection, project management, monitoring, data management, logistics, and more.

Go social with us

Follow us on social networks:

Privacy policy, Terms of service, Site map, Employees login



© 2001—2021 Global Clinical Trials, LLC

All rights reserved.